Roche Details ADA 2026 Obesity Portfolio Presentations

Key Takeaways

• Roche is previewing late-breaking Phase II data at ADA 2026 for enicepatide from CT388-103 and for petrelintide from ZUPREME-1.
• Roche says both assets are moving into Phase III development, and a Phase II multi-arm fixed-dose combination trial is planned toward mid-2026.
• Roche frames the update around efficacy, safety, tolerability, treatment adherence, and more tailored treatment options, but those interpretations come from the company release.

Roche says it will present new data from its obesity portfolio at the 2026 Scientific Sessions of the American Diabetes Association, with enicepatide and petrelintide at the center of the update. The company previewed late-breaking Phase II presentations for both agents, said each program is moving into Phase III, and said a Phase II multi-arm fixed-dose combination study is planned toward mid-2026.

Enicepatide, also identified as CT-388, is described by Roche as a dual GLP-1/GIP receptor agonist for obesity and related comorbidities. The late-breaking dataset is from Phase II CT388-103, and Roche also highlighted Phase II CT388-104 in people living with obesity or overweight plus type 2 diabetes. Roche further describes enicepatide as designed for minimal to no beta-arrestin recruitment, with biased signaling intended to limit receptor internalisation and desensitisation. Roche positions enicepatide as a potential medicine on its own and as a backbone for future combination approaches.

Petrelintide is described by Roche as an investigational long-acting human amylin analog suitable for once-weekly subcutaneous administration. Late-breaking Phase II data are expected from ZUPREME-1, while the ongoing Phase II ZUPREME-2 study is described as evaluating petrelintide versus placebo in obesity or overweight with type 2 diabetes. Roche also says the molecule was designed for chemical and physical stability, with no fibrillation around neutral pH, allowing co-formulation and co-administration with other peptides.

Roche says both enicepatide and petrelintide are moving into Phase III development, while a Phase II multi-arm trial of fixed-dose enicepatide and petrelintide combinations is planned to start toward mid-2026. The ADA Scientific Sessions presentations are scheduled for 5 to 8 June 2026, and the release notes that full abstracts will be available in Diabetes. Roche also scheduled a virtual investor and analyst event for 8 June 2026 focused on the Phase II enicepatide and petrelintide updates.